28 results about "EDEMA RETINAL" patented technology

The present invention provides a compound of Formula Iand pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The invention provides extracellular vesicle proteins sPTPRG and Vincin of a biomarker for detecting retinal vein obstructive macular edema (RVO-ME) anti-VEGF treatment typing, the difference of the expression quantity of the extracellular vesicle proteins in aqueous humor of a patient is analyzed, the protein with remarkable expression difference is screened out, the protein can be used as the biomarker for RVO-ME treatment, and the application of the biomarker for detecting the anti-VEGF treatment typing of the retinal vein obstructive macular edema (RVO-ME) anti-VEGF treatment typing of the RVO-ME anti-VEGF treatment typing is facilitated. Important guidance is provided for personalized treatment of RVO-ME, and the method has a wide clinical application prospect.

The present invention relates to fluorinated compounds of formula I and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing the fluorinated compounds of the invention, and methods of treating macular degeneration, diabetic retinopathy (DR), macular edema, diabetic macular edema (DME), and macular edema following retinal vein occlusion (RVO), by administering these compounds and pharmaceutical compositions to subjects in need thereof.

The present invention relates to 3, 5-diaminotriazole derivatives of formula (I) and pharmaceutical or veterinary compositions comprising such derivatives. It further relates to the use of the compounds of formula (I) for the treatment of ocular diseases, preferably diabetic retinopathy, macular degeneration, neovascular glaucoma, macular edema or Steckstroke disease.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The invention relates to a traditional Chinese medicine composition for treating macular edema, which is prepared from the following traditional Chinese medicines in parts by weight: 5-35 parts of astragalus mongholicus, 1-30 parts of radix rehmanniae recen, 1-30 parts of radix angelicae, 1-30 parts of rhizoma atractylodis macrocephalae and 1-30 parts of rhizoma atractylodis macrocephalae. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 1-30 parts of poria cocos, 1-20 parts of radix achyranthis bidentatae, 1-20 parts of moutan bark, 1-20 parts of fructus gardeniae, 1-20 parts of radix salviae miltiorrhizae, 1-20 parts of radix scrophulariae, 1-20 parts of radix ophiopogonis, 1-20 parts of radix paeoniae alba, 1-15 parts of radix curcumae, 1-10 parts of radix notoginseng and 1-10 parts of lotus leaves. The traditional Chinese medicine composition can effectively relieve macular edema after macular anterior membrane vitrectomy, has positive effects on improving the inflammatory state, microcirculation and metabolic function of a macular region of a patient, and is safe in clinical use.

To provide treatment of AMD using an AAV2 variant with aflibercept.SOLUTION: The present disclosure provides pharmaceutical compositions and methods thereof for treatment of age-related macular degeneration (AMD) in a subject by administering intravitreally a pharmaceutical composition adapted for gene therapy, comprising a vector having a nucleic acid sequence that encodes aflibercept. The present disclosure relates to pharmaceutical compositions and methods for prevention or treatment of neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), diabetic retinopathy (DR) in patients with DME, retinal vein occlusion, and related eye diseases or conditions, in a primate or human subject by administering intravitreally or subretinally a pharmaceutical composition comprising a pharmaceutically effective amount of a vector or viral particles (e.g., rAAV) comprising a nucleic acid encoding aflibercept or a functional fragment or variant thereof.SELECTED DRAWING: None

The present disclosure relates to chimeric molecules which are fusion proteins comprising two components: an Ang-2 binding peptide linked to either a VEGF antibody or a VEGF receptor-Fc fusion protein. The Ang2 peptide, VEGF antibody, and VEGF receptor-Fc fusion proteins are each defined below with reference to percent identity to a reference sequence. The chimeric molecule is a fusion protein, dual antagonist of Ang2 and VEGF for treatment of cancers, proliferative retinopathies, neovascular glaucoma, macular edema, AMD, and rheumatoid arthritis.

The present invention relates to novel methods, uses and compositions of annexin A5 protein as combination therapy with one or more anti-VEGF agents, the present invention relates to compounds, for example, for the prevention or treatment of macular edema, retinal vein occlusion and / or one or more diseases, conditions or conditions associated with and / or caused by macular edema or retinal vein occlusion, and / or other conditions suitable for treatment with anti-VEGF agents. In a preferred embodiment, the annexin A5 is administered systemically, such as intravenously.

The application discloses a kind of based on MEA-Net network's modeling method of multi-expert system, the application includes data pre-processing, cutting and proportionally distributing production image data and label data set;In order to improve fundus retinal lesion classification accuracy, the application designs Multi-Expert attention Net network model.Input module is preliminary extracted to data, replaceable expert network module is responsible for the depth analysis of feature, and voting module is strengthened by separating channel adjacent module on channel space to feature, and output weight realizes expert voting, finally, classification result is obtained by output module.The application can use the picture information of optical coherence tomography, can analyze and extract the characteristics of the four types of macular edema degeneration performances of OCT image PED, SRF, IRF, HRF, and lay the foundation for subsequent retinal disease classification and analysis to improve efficiency.

The invention relates to the technical field of image data processing, in particular to a macular oedema dynamic change monitoring method based on an OCT (optical coherence tomography) tomographic image, which comprises the following steps: acquiring a reference OCT image, a micro-angle change OCT image and an OCTA blood flow image of an eye macular area of a patient; determining the change intensity of pixel points by using a gray value change sequence in the OCTA blood flow image sequence, and determining a macular oedema existing area in the reference OCT image based on the change intensity; performing peak detection on the gray histogram of the macular oedema existing area based on the gray features of the cyst area to obtain a cyst candidate area; and determining a cyst candidate area, and obtaining a cyst area in the reference OCT image by using a gray value sequence of pixel points in the aligned cyst candidate area. According to the method, the influence of the vessel shadow is eliminated, the segmented cyst part is more accurate and complete, and the dynamic change monitoring effect is remarkably improved.

The invention provides a construction method of a retinal vein occlusion animal model, and belongs to the technical field of medicines. The method comprises the following steps of: performing eyeball surface anesthesia on an anesthetized non-human primate animal, puncturing an eyeball after disinfection to establish two sclera tunnels, respectively inserting an illumination optical fiber and an intraocular laser optical fiber into the two sclera tunnels, then injecting a photosensitizer through limb vein, immediately performing laser photocoagulation on the retinal vein under illumination of the illumination optical fiber after injection, and performing laser photocoagulation on the retinal vein under the illumination of the illumination optical fiber. And obtaining the retinal vein occlusion animal model. According to the method, the retinal vein occlusion model can be successfully constructed, secondary macular edema and vascular recanalization are carried out for a long time and can be maintained for 4-5 weeks, the manifestation sign of retinal hemorrhage after retinal vein occlusion is close to that of human beings, and the method has clinical drug responsiveness, shows the clinical research value and has good application prospects. And a good research model is provided for research in the aspects of etiology, pathology and therapeutics.

The present disclosure relates to the use of, and to methods of using, DHODH inhibitor compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions including a DHODH inhibitor compound for the treatment of ocular diseases. The ocular diseases include, but are not limited to, proliferative vitreoretinopathy, cystoid macular edema, central serous retinopathy, diabetic retinopathy, endophthalmitis, epiretinal membrane, and toxoplasmosis. The present disclosure also relates to the use of, and to methods of using, DHODH inhibitor compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions including a DHODH inhibitor compound to inhibit glial scar formation or reduce glial scar length.

The invention provides a fundus macular oedema image processing method based on improved YOLOv11 and DeepSeek, and relates to the technical field of ophthalmic disease screening, and the method specifically comprises the steps: employing an improved YOLOv11 network structure, adding a lightweight dynamic convolution module LDConv module and a convolution block attention module CBAM, dynamically adjusting the shape and size of a convolution kernel, and carrying out the detection of the fundus macular oedema image. Multi-scale lesion characteristics such as macular edema and exudates are accurately captured; an attention map is generated through a channel and a space attention mechanism, key lesion areas of macular edema are preferentially concerned, interference of background noise is inhibited, and therefore accuracy and robustness of lesion recognition are further improved; a DeepSeek large language model is introduced, and on the basis of a detection result, personalized diagnosis and treatment suggestions conforming to clinical guidelines are generated in combination with clinical information (such as age, pathogenesis and treatment history) of patients; the system provides a structured treatment scheme and a follow-up visit plan and assists doctors in making more scientific and personalized decisions.

This invention relates to the application of an AAV carrying anti-VEGF recombinant protein in the prevention or treatment of proliferative diabetic retinopathy. After loading Fc-engineered VEGF antibody into an AAV vector, it can be used in drugs for the treatment of proliferative diabetic retinopathy. After injection, it can significantly improve the visual function of patients and reduce macular edema after a single dose. The anti-VEGF recombinant protein can be expressed for a long time, and can maintain the drug effect over a long period of time.

The present disclosure relates to the use of, and to methods of using, DHODH inhibitor compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions including a DHODH inhibitor compound for the treatment of ocular diseases. The ocular diseases include, but are not limited to, proliferative vitreoretinopathy, cystoid macular edema, central serous retinopathy, diabetic retinopathy, endophthalmitis, epiretinal membrane, and toxoplasmosis. The present disclosure also relates to the use of, and to methods of using, DHODH inhibitor compounds, pharmaceutically acceptable salts thereof, and pharmaceutical compositions including a DHODH inhibitor compound to inhibit glial scar formation or reduce glial scar length.

The present invention provides compounds of Formula (I) and pharmaceutical compositions comprising one or more of the compounds, and methods of using the compounds to treat or prevent one or more conditions that can benefit from the inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular edema, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

An ophthalmic formulation for treating macular edema, optic neuritis, and non-infectious endophthalmitis, comprising an active ingredient for treating an eye disease and a carrier or auxiliary material for the ophthalmic formulation, wherein the active ingredient for treating the eye disease is a glucocorticoid and / or nonsteroidal drug, and the carrier or auxiliary material for the ophthalmic formulation contains a surfactant, an ionic polymer, and a solvent, or the carrier or auxiliary material for the ophthalmic formulation contains low-degree-of-polymerization povidone, medium-degree-of-polymerization povidone, and a solvent. [Solution] This ophthalmic formulation, administered by eye drops, carries (encapsulates) glucocorticoid and / or nonsteroidal drugs, passes through the anterior segment of the eye, and is transported to the posterior segment to treat macular edema, optic neuritis, and non-infectious endophthalmitis. It has excellent clinical value and very positive social significance.

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age related macular edema, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

The invention provides a CRVO-ME early screening method and system fusing multi-source ophthalmic examination data, and relates to the technical field of intelligent screening combining the medical information technology and ophthalmic clinical diagnose.The method comprises the steps that the multi-source ophthalmic examination data including clinical data and ophthalmic image data are obtained, and the multi-source ophthalmic examination data are obtained; adopting a multiple interpolation technology to fill missing values to generate a complete data set; carrying out single-variable analysis on the complete data set, and screening out an initial variable set related to CRVO-ME; inputting the set into a pre-constructed LASSO-Logistic regression model, carrying out compression screening on variables by utilizing an L1 regularization technology, determining an optimal regularization parameter lambda value in combination with grid search and cross validation, and screening out a key risk factor subset according to the optimal regularization parameter lambda value; and finally, an LASSO-Logistic risk prediction model is constructed based on the subset, and early screening of CRVO-ME is realized. According to the method, the early screening efficiency of retinal central vein occlusion and macular edema is improved.

The application provides an extracellular vesicle protein sPTPRG, Vinculin for detecting biomarkers of anti-VEGF treatment classification of retinal vein occlusion macular edema (RVO-ME), and by analyzing differences in expression amounts of extracellular vesicle proteins in aqueous humor of patients, proteins with significant expression differences are screened out, which can be used as biomarkers for RVO-ME treatment, important guidance is provided for personalized treatment of RVO-ME, and has wide clinical application prospects.

This invention provides an ophthalmic preparation for treating macular edema, optic neuritis, and non-infectious endophthalmitis. It is a preparation composed of an active ingredient for treating eye diseases and an ophthalmic preparation carrier or excipients. The active ingredient for treating eye diseases is a glucocorticoid and / or a non-steroidal anti-inflammatory drug (NSAID). The ophthalmic preparation carrier or excipients contain the following components: low-polymerization povidone, medium-polymerization povidone, and a solvent. This ophthalmic preparation of the present invention can be administered via eye drops, carrying (encapsulating) glucocorticoids and / or NSAIDs through the anterior segment of the eye and delivering them to the posterior segment to treat macular edema, optic neuritis, and non-infectious endophthalmitis. It has extremely excellent clinical value and very positive social significance.

The present invention provides compounds of Formula I and pharmaceutical compositions comprising one or more of the compounds, and methods of using the compounds to treat or prevent one or more disease states that can benefit from the inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular edema, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.